Skip to main content
ABION Inc. logo

ABION Inc. — Investor Relations & Filings

Ticker · 203400 ISIN · KR7203400007 KO Professional, scientific and technical activities
Open in API
Filings indexed 409 across all filing types
Latest filing 2021-11-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 203400

About ABION Inc.

https://abionbio.com/en/

ABION Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative medicines, focusing on first-in-class and best-in-class therapeutics for oncology and viral diseases. The company's lead oncology asset is ABN401, a selective c-Met tyrosine kinase inhibitor (TKI) designed to treat non-small cell lung cancer (NSCLC) with MET mutations, which has shown a favorable safety profile. Another key pipeline candidate is ABN501, a novel monoclonal antibody targeting Claudin-3 for various cancers. Beyond oncology, ABION is developing ABN101, a second-generation Interferon-β formulated as a broad-spectrum anti-viral inhaler for respiratory infections. The company aims to commercialize its assets in global markets through internationally recognized clinical processes.

Recent filings

Filing Released Lang Actions
분기보고서 (2021.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Abion Inc.' (에이비온주식회사) covering the period from January 1, 2021, to September 30, 2021. It contains detailed financial information, company history, capital structure, and business operations, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2021
2021-11-15 Korean
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the results of an Extraordinary General Meeting (EGM) for the company 'Abion'. It lists the agenda items (resolutions) and the outcome of the votes (approved as proposed), as well as details regarding the appointment of a new director. This falls under the category of Declaration of Voting Results.
2021-11-04 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to specific executives, including the number of shares, exercise price, and valuation methodology. This type of disclosure regarding capital structure changes and equity-based compensation for directors/employees falls under the category of regulatory filings that do not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes). Therefore, it is classified as a general regulatory filing.
2021-11-04 Korean
주식매수선택권부여에관한신고
Remuneration Information Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees, including the number of shares, exercise price, and valuation methodology. This type of disclosure regarding capital structure changes and equity-based compensation falls under the category of regulatory filings for corporate actions that do not fit into specific categories like dividends or M&A.
2021-11-04 Korean
[기재정정]주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Extraordinary General Meeting' (임시주주총회 소집공고) which includes details about the meeting date, location, agenda items (such as articles of incorporation changes and director appointments), and voting procedures. It also contains a section on 'Management Reference Matters' (경영참고사항) which provides business overviews, financial highlights, and board activity reports. This type of document is standard for providing shareholders with the necessary information to vote at an upcoming meeting, which falls under the Proxy Solicitation & Information Statement category.
2021-10-26 Korean
[기재정정]주주총회소집결의
AGM Information Classification · 98% confidence The document is a regulatory filing from the Korean stock exchange (KIND) regarding a 'Resolution to Convene a General Meeting of Shareholders' (주주총회소집결의). It provides details on the agenda, date, location, and specific director nominations for an upcoming Extraordinary General Meeting. While it relates to a meeting, it is a formal regulatory notice of the meeting's agenda and logistics rather than a presentation or proxy solicitation material. Given the specific nature of the filing as a formal notice of a shareholder meeting, it falls under the category of Regulatory Filings (RNS) as it is a standard corporate disclosure.
2021-10-20 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.